Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2012 | Original Paper

miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes

Authors: Yong-Kui Zhang, Wang-Yu Zhu, Jian-Ying He, Dong-Dong Chen, Yan-Yan Huang, Han-Bo Le, Xiao-Guang Liu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2012

Abstract

Purpose

We investigated whether miRNA expression profiles can distinguish and predict outcome of non-small-cell lung carcinoma (NSCLC) patients with different histological subtypes.

Methods

High-throughput microarray was used to measure miRNA expression levels in six NSCLC samples. Subsequently, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to verify findings in an independent set of 54 squamous-cell lung carcinomas (SCC), 51 lung adenocarcinomas (AD), and paired adjacent non-neoplastic lung tissue.

Results

We showed that, compared to adjacent non-neoplastic lung tissues, the expressions of miR-125a-5p and let-7e were decreased in AD and SCC samples, while increased expressions of miR-93, miR-205, and miR-221 were observed in SCC samples. In addition, miR-205 expression was significantly higher in SCC patients with lymph node metastasis. Lower let-7e expression was associated with lymph node metastasis, >3 cm tumor size, and differentiation of the NSCLC AD subtype. High levels of miR-100 expression also correlated with the AD subtype in current smokers. Moreover, induction of miR-93 and miR-205 expressions and reduction of let-7e were strongly associated with shorter overall survival in SCC patients, whereas AD patient survival was only associated with reduced let-7e.

Conclusions

We identified differential expression profiles of miRNAs in AD and SCC. More importantly, in addition to morphology and immunocytochemistry approaches, we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments. Furthermore, our results suggest a strong correlation between high expression of miR-100 and AD patients with history of heavy smoking.

Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH (2010) Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16(2):610–619PubMedCrossRef

Boffetta P, Jayaprakash V, Yang P et al (2011) Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case–control studies in the international lung cancer consortium (ILCCO). Cancer Causes Control 22:1–7CrossRef

Frost G, Darnton A, Harding AH (2011) The effect of smoking on the risk of lung cancer mortality for asbestos workers in Great Britain. Ann Occup Hyg 55(3):239–241PubMedCrossRef

Gregory PA, Bert AG, Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593–601PubMedCrossRef

Hecht SS (1999) Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91(14):1194–1210PubMedCrossRef

Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M (2008) The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 3(12):1468–1481PubMedCrossRef

Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S (2009) Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 23(3):806–812PubMedCrossRef

Johnson CD, Esquela-Kerscher A, Stefani G et al (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67(16):7713–7722PubMedCrossRef

Jorda M, Gomez-Fernandez C, Garcia M et al (2009) P63 differentiates subtypes of non-small cell carcinomas of lung in cytologic samples. Cancer Cytopathol 117(1):46–50CrossRef

Landi MT, Zhao Y, Rotunno M et al (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16(2):430–441PubMedCrossRef

Lebanony D, Benjamin H, Gilad S et al (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27(12):2030–2037PubMedCrossRef

Lee YS, Dutta A (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21(9):1025–1030PubMedCrossRef

Li Y, VandenBoom TG, Kong D et al (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69(16):6704–6712PubMedCrossRef

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[delta][delta] CT method. Methods 25(4):402–408PubMedCrossRef

Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838PubMedCrossRef

Majid S, Dar AA, Saini S et al (2010) MicroRNA-205 directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116(24):5637–5649PubMedCrossRef

Medina PP, Slack FJ (2008) MicroRNAs and cancer: an overview. Cell Cycle 7:2485–2492PubMedCrossRef

Miller YE (2005) Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 33(3):216–223PubMedCrossRef

Ragusa M, Majorana A, Statello L et al (2010) Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 9(12):3396–3403PubMedCrossRef

Raponi M, Dossey L, Jatkoe T et al (2009) MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69(14):5583–5776CrossRef

Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551PubMedCrossRef

Takamizawa J, Konishi H, Yanagisawa K et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11):3753–3756PubMedCrossRef

Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM (2006) Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20(16):2202–2207PubMedCrossRef

Van Pottelberge GR, Mestdagh P, Bracke KR et al (2010) MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 183:898–906PubMedCrossRef

Vescovo VD, Cantaloni C, Cucino A et al (2011) MiR-205 expression levels in non-small cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 35(2):268–275PubMedCrossRef

Wang B, Howel P, Bruheim S et al (2011) Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. PLoS One 6(2):e17167PubMedCrossRef

Xing L, Todd NW, Yu L, Fang HB, Jiang F (2010) Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 23(8):1157–1164PubMedCrossRef

Yanaihara N, Caplen N, Bowman E et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3):189–198PubMedCrossRef

Yu SL, Chen HY, Chang GC et al (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1):48–57PubMedCrossRef

Title: miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes
Authors: Yong-Kui Zhang
Wang-Yu Zhu
Jian-Ying He
Dong-Dong Chen
Yan-Yan Huang
Han-Bo Le
Xiao-Guang Liu
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1240-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2012

Expression and biological role of δ-catenin in human ovarian cancer

Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?

HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents

Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival

Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer

Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page